495 related articles for article (PubMed ID: 29630890)
21. Sacral neuromodulation with an implantable pulse generator in children with lower urinary tract symptoms: 15-year experience.
Groen LA; Hoebeke P; Loret N; Van Praet C; Van Laecke E; Ann R; Vande Walle J; Everaert K
J Urol; 2012 Oct; 188(4):1313-7. PubMed ID: 22902022
[TBL] [Abstract][Full Text] [Related]
22. Do Patients Discontinue Overactive Bladder Medications after Sacral Neuromodulation?
Amin K; Moskowitz D; Kobashi KC; Lee UJ; Lucioni A
J Urol; 2019 May; 201(5):973-978. PubMed ID: 30694936
[TBL] [Abstract][Full Text] [Related]
23. Sacral neuromodulation in patients with idiopathic overactive bladder after initial botulinum toxin therapy.
Smits MA; Oerlemans D; Marcelissen TA; Van Kerrebroeck PE; De Wachter SG
J Urol; 2013 Dec; 190(6):2148-52. PubMed ID: 23872028
[TBL] [Abstract][Full Text] [Related]
24. [Neuromodulation of lower urinary tract dysfunction].
Kessler TM; de Wachter S
Urologe A; 2017 Dec; 56(12):1591-1596. PubMed ID: 29063170
[TBL] [Abstract][Full Text] [Related]
25. The effect of sacral neuromodulation on pudendal nerve function and female sexual function.
Parnell BA; Howard JF; Geller EJ
Neurourol Urodyn; 2015 Jun; 34(5):456-60. PubMed ID: 24615871
[TBL] [Abstract][Full Text] [Related]
26. Disparities in the Use of Sacral Neuromodulation among Medicare Beneficiaries.
Laudano MA; Seklehner S; Sandhu J; Reynolds WS; Garrett KA; Milsom JW; Te AE; Kaplan SA; Chughtai B; Lee RK
J Urol; 2015 Aug; 194(2):449-53. PubMed ID: 25846418
[TBL] [Abstract][Full Text] [Related]
27. New Technologies and Applications in Sacral Neuromodulation: An Update.
De Wachter S; Knowles CH; Elterman DS; Kennelly MJ; Lehur PA; Matzel KE; Engelberg S; Van Kerrebroeck PEV
Adv Ther; 2020 Feb; 37(2):637-643. PubMed ID: 31875299
[TBL] [Abstract][Full Text] [Related]
28. Real World Performance of Sacral Neuromodulation and OnabotulinumtoxinA for Overactive Bladder: Focus on Safety and Cost.
Chughtai B; Clemens JQ; Thomas D; Sun T; Ghomrawi H; Sedrakyan A
J Urol; 2020 Jan; 203(1):179-184. PubMed ID: 31347949
[TBL] [Abstract][Full Text] [Related]
29. Onset of Action of Sacral Neuromodulation in Lower Urinary Tract Dysfunction-What is the Optimal Duration of Test Stimulation?
Jairam R; Drossaerts J; Marcelissen T; van Koeveringe G; van Kerrebroeck P
J Urol; 2018 Jun; 199(6):1584-1590. PubMed ID: 29291416
[TBL] [Abstract][Full Text] [Related]
30. A prospective, multicenter study of a novel, miniaturized rechargeable sacral neuromodulation system: 12-month results from the RELAX-OAB study.
Blok B; Van Kerrebroeck P; de Wachter S; Ruffion A; Van der Aa F; Jairam R; Perrouin-Verbe MA; Elneil S
Neurourol Urodyn; 2019 Feb; 38(2):689-695. PubMed ID: 30592526
[TBL] [Abstract][Full Text] [Related]
31. Battery explantation after sacral neuromodulation in the Medicare population.
Cameron AP; Anger JT; Madison R; Saigal CS; Clemens JQ;
Neurourol Urodyn; 2013 Mar; 32(3):238-41. PubMed ID: 22847359
[TBL] [Abstract][Full Text] [Related]
32. Exhausted implanted pulse generator in sacral nerve stimulation for faecal incontinence: What next in daily practice for patients?
Duchalais E; Meurette G; Perrot B; Wyart V; Kubis C; Lehur PA
Int J Colorectal Dis; 2016 Feb; 31(2):439-44. PubMed ID: 26552785
[TBL] [Abstract][Full Text] [Related]
33. Single Institutional Experience with Single Stage Sacral Neuromodulation: Cost Savings and Outcomes in a Contemporary Case Series.
Lee W; Artenstein D; Tenggardjaja CF; Lee UJ; Lucioni A; Reyblat P; Kobashi KC
J Urol; 2020 Mar; 203(3):604-610. PubMed ID: 31584846
[TBL] [Abstract][Full Text] [Related]
34. [Results of sacral posterior neuromodulation on voiding disorders and impact on sexuality based on a single-center study].
Ferhi K; Miaadi N; Tanneau Y; Leroi AM; Sibert L; Grise P
Prog Urol; 2008 Mar; 18(3):160-6. PubMed ID: 18472068
[TBL] [Abstract][Full Text] [Related]
35. Sacral neuromodulation for the treatment of overactive bladder: systematic review and future prospects.
Tilborghs S; De Wachter S
Expert Rev Med Devices; 2022 Feb; 19(2):161-187. PubMed ID: 35061951
[TBL] [Abstract][Full Text] [Related]
36. Differences in sacral neuromodulation device infection rates based on preoperative antibiotic selection.
Haraway AM; Clemens JQ; He C; Stroup C; Atiemo HO; Cameron AP
Int Urogynecol J; 2013 Dec; 24(12):2081-5. PubMed ID: 23695383
[TBL] [Abstract][Full Text] [Related]
37. Neuromodulation for fecal incontinence: outcome in 16 patients with definitive implant. The initial Italian Sacral Neurostimulation Group (GINS) experience.
Ganio E; Ratto C; Masin A; Luc AR; Doglietto GB; Dodi G; Ripetti V; Arullani A; Frascio M; BertiRiboli E; Landolfi V; DelGenio A; Altomare DF; Memeo V; Bertapelle P; Carone R; Spinelli M; Zanollo A; Spreafico L; Giardiello G; de Seta F
Dis Colon Rectum; 2001 Jul; 44(7):965-70. PubMed ID: 11496076
[TBL] [Abstract][Full Text] [Related]
38. Refractory overactive bladder after urethrolysis for bladder outlet obstruction: management with sacral neuromodulation.
Starkman JS; Duffy JW; Wolter CE; Kaufman MR; Scarpero HM; Dmochowski RR
Int Urogynecol J Pelvic Floor Dysfunct; 2008 Feb; 19(2):277-82. PubMed ID: 17671752
[TBL] [Abstract][Full Text] [Related]
39. Results of a prospective, multicenter study evaluating quality of life, safety, and efficacy of sacral neuromodulation at twelve months in subjects with symptoms of overactive bladder.
Noblett K; Siegel S; Mangel J; Griebling TL; Sutherland SE; Bird ET; Comiter C; Culkin D; Bennett J; Zylstra S; Kan F; Berg KC
Neurourol Urodyn; 2016 Feb; 35(2):246-51. PubMed ID: 25546568
[TBL] [Abstract][Full Text] [Related]
40. Physician Use of Sacral Neuromodulation Among Medicare Beneficiaries With Overactive Bladder and Urinary Retention.
Suskind AM; Clemens JQ; Zhang Y; Hollenbeck BK
Urology; 2015 Jul; 86(1):30-4. PubMed ID: 26026856
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
